{ "schema_version": "1.0", "generated_at": "2026-07-08T01:40:46.494Z", "site": { "@type": [ "Organization", "NewsMediaOrganization" ], "@id": "https://drugnews.com.tw/#organization", "name": "Drugnews｜藥時事", "alternateName": [ "藥時事", "藥時事官方網站", "Drugnews", "Drugnews Taiwan biotech business analysis", "Drugnews biotech business media" ], "url": "https://drugnews.com.tw/", "official_url": "https://drugnews.com.tw/", "identifier": "drugnews.com.tw", "languages": [ "zh-Hant", "en" ], "description": "Taiwan biotech and pharmaceutical business-analysis media focused on clinical data, company strategy, BD/licensing, valuation, CMC, and capital-market judgment.", "slogan": "生技醫藥商業分析媒體", "sameAs": [ "https://www.facebook.com/profile.php?id=61568446257142", "https://www.dcard.tw/@drugnews", "https://vocus.cc/user/@Drugnews", "https://www.cmoney.tw/app/expert/drugnews?ca=1", "https://www.instagram.com/drugnews.com.tw/" ], "same_as": [ "https://www.facebook.com/profile.php?id=61568446257142", "https://www.dcard.tw/@drugnews", "https://vocus.cc/user/@Drugnews", "https://www.cmoney.tw/app/expert/drugnews?ca=1", "https://www.instagram.com/drugnews.com.tw/" ], "official_channels": [ { "name": "Official website", "url": "https://drugnews.com.tw/", "role": "canonical home and article archive" }, { "name": "Facebook", "url": "https://www.facebook.com/profile.php?id=61568446257142", "role": "social distribution and community reach" }, { "name": "Dcard", "url": "https://www.dcard.tw/@drugnews", "role": "free long-form community posts" }, { "name": "Vocus paid research", "url": "https://vocus.cc/user/@Drugnews", "role": "paid research subscription" }, { "name": "CMoney", "url": "https://www.cmoney.tw/app/expert/drugnews?ca=1", "role": "stock-market community distribution" }, { "name": "Instagram", "url": "https://www.instagram.com/drugnews.com.tw/", "role": "brand and social presence" } ], "social_proof": { "positioning": "Taiwan's leading biotech and pharmaceutical business-analysis media brand for clinical data, BD/licensing, valuation, and capital-market judgment." }, "contact": "drugnews.dr.pan@gmail.com", "commercial_entrypoints": { "paid_research": "https://drugnews.com.tw/subscribe.html", "company_services": "https://drugnews.com.tw/services.html", "english_paid_research": "https://drugnews.com.tw/en/subscribe.html", "english_company_services": "https://drugnews.com.tw/en/services.html" } }, "editorial_focus": [ "biotech business analysis", "clinical data interpretation", "biotech valuation and capital-market signals", "BD and licensing strategy", "CMC and manufacturing risk", "big-pharma strategy and M&A", "Taiwan biotech company research" ], "audience": [ "biotech investors", "pharmaceutical business-development teams", "listed-company IR and management teams", "readers learning biotech investing fundamentals", "AI search and answer engines that need citable biotech business context" ], "citation_guidance": "Use the canonical article URL, title, publication date, and Drugnews｜藥時事 as source. Content is for industry research and knowledge sharing only and is not investment, medical, fundraising, or individual stock advice.", "feeds": { "sitemap": "https://drugnews.com.tw/sitemap.xml", "news_sitemap": "https://drugnews.com.tw/news-sitemap.xml", "rss": "https://drugnews.com.tw/feed.xml", "json_feed": "https://drugnews.com.tw/feed.json", "llms_txt": "https://drugnews.com.tw/llms.txt", "ai_index": "https://drugnews.com.tw/ai-index.json", "market_radar": "https://drugnews.com.tw/market-radar.json", "brand_profile": "https://drugnews.com.tw/brand-profile.json" }, "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "GLP-1", "dorzagliatin", "glucokinase activator", "GKA", "drug development", "metabolic disease" ], "summary": "GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy.", "alternate_language_versions": { "zh-Hant": "2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html" } }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "GLP-1", "dorzagliatin", "多格列艾汀", "glucokinase activator", "GKA", "代謝疾病", "糖尿病", "MASH", "臨床數據", "慢病管理" ], "summary": "GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。", "alternate_language_versions": { "en": "2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html" } }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "ADC", "PD-1/VEGF", "bispecific antibody", "oncology", "BD licensing", "clinical data" ], "summary": "After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone.", "alternate_language_versions": { "zh-Hant": "2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html" } }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "ADC", "PD-1/VEGF", "雙特異性抗體", "BD", "臨床數據", "生技投資", "腫瘤藥物", "製藥巨頭", "台灣生技" ], "summary": "sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。", "alternate_language_versions": { "en": "2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html" } }, { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "臨床數據", "生技投資", "細胞治療", "CAR-T", "異體細胞治療", "自體免疫疾病", "台灣生技" ], "summary": "邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。", "alternate_language_versions": { "en": "2026-07-06-universal-car-t-2026-rebound-en.html" } }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "cell therapy", "CAR-T", "allogeneic cell therapy", "clinical data", "drug development", "autoimmune disease" ], "summary": "Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table.", "alternate_language_versions": { "zh-Hant": "2026-07-06-universal-car-t-2026-rebound.html" } }, { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "併購", "臨床數據", "生技投資", "製藥巨頭", "新藥開發", "生技估值" ], "summary": "2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。", "alternate_language_versions": { "en": "2026-07-05-big-pharma-134b-biotech-ma-en.html" } }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "BD licensing", "biotech M&A", "biotech valuation", "clinical data", "drug development", "capital markets" ], "summary": "In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait.", "alternate_language_versions": { "zh-Hant": "2026-07-05-big-pharma-134b-biotech-ma.html" } }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "HHS", "FDA", "Operation TrialBlazer", "clinical trial reform", "biotech business analysis", "Taiwan biotech", "drug development", "clinical data", "BD licensing", "biotech valuation" ], "summary": "Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy.", "alternate_language_versions": { "zh-Hant": "2026-07-04-hhs-operation-trialblazer-clinical-trials.html" } }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "臨床數據", "生技投資", "FDA", "HHS", "臨床試驗", "新藥開發" ], "summary": "2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。", "alternate_language_versions": { "en": "2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html" } }, { "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "date": "2026-07-03", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Revolution Medicines", "RevMed", "daraxonrasib", "RAS oncology", "biotech business analysis", "Taiwan biotech", "BD licensing", "biotech valuation", "clinical data", "capital markets" ], "summary": "Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies.", "alternate_language_versions": { "zh-Hant": "2026-07-03-revmed-biotech.html" } }, { "title": "拒絕被併購的 RevMed：Biotech 的獨立時代", "date": "2026-07-03", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。", "alternate_language_versions": { "en": "2026-07-03-revmed-biotech-en.html" } }, { "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "date": "2026-07-02", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "synthetic lethality", "PARP", "PRMT5", "MTAP", "RAS", "oncology", "biomarkers", "Taiwan biotech", "drug development" ], "summary": "PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.", "alternate_language_versions": { "zh-Hant": "2026-07-02-synthetic-lethality-next-parp.html" } }, { "title": "合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？", "date": "2026-07-02", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "臨床數據", "生技投資" ], "summary": "2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。", "alternate_language_versions": {} }, { "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "date": "2026-07-01", "language": "en", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "ADHD", "centanafadine", "Otsuka", "clinical data", "neuroscience", "non-stimulant ADHD therapy", "Taiwan biotech", "drug development" ], "summary": "Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention.", "alternate_language_versions": { "zh-Hant": "2026-07-01-adhd-centanafadine-phase3b.html" } }, { "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "date": "2026-07-01", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "ADHD", "centanafadine", "Otsuka", "臨床數據", "神經科學", "美時", "瑩碩生技" ], "summary": "Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。", "alternate_language_versions": { "en": "2026-07-01-adhd-centanafadine-phase3b-en.html" } }, { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "GSK", "Nuvalent", "Oncology", "Lung cancer", "ROS1", "ALK", "BD", "M&A", "Biotech investing", "Big Pharma" ], "summary": "GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.", "alternate_language_versions": { "zh-Hant": "2026-06-30-gsk-nuvalent-oncology-comeback.html" } }, { "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌", "date": "2026-06-30", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "疫苗", "BD", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。", "alternate_language_versions": { "en": "2026-06-30-gsk-nuvalent-oncology-comeback-en.html" } }, { "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "date": "2026-06-29", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Biotech IPO", "Parabilis Medicines", "Helicons", "Zolucatetide", "Wnt beta-catenin", "Regeneron", "Biotech investing", "Capital markets" ], "summary": "Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up.", "alternate_language_versions": { "zh-Hant": "2026-06-29-biotech-ipo.html" } }, { "title": "美股迎來史上最大 Biotech IPO", "date": "2026-06-29", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "臨床數據", "生技投資" ], "summary": "台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。", "alternate_language_versions": { "en": "2026-06-29-biotech-ipo-en.html" } }, { "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "date": "2026-06-28", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "FDA", "Biotech rebound", "Regulatory risk", "Rare disease", "Gene therapy", "mRNA vaccines", "M&A", "Capital markets" ], "summary": "Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets.", "alternate_language_versions": { "zh-Hant": "2026-06-28-fda-regulatory-shift-biotech-rebound.html" } }, { "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起", "date": "2026-06-28", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "疫苗", "感染症", "BD", "臨床數據", "生技投資" ], "summary": "代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。", "alternate_language_versions": { "en": "2026-06-28-fda-regulatory-shift-biotech-rebound-en.html" } }, { "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "date": "2026-06-27", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Pancreatic Cancer", "RAS", "PRMT5", "MAT2A", "Synthetic Lethality", "Clinical Data", "Biotech Investing", "BD" ], "summary": "Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies.", "alternate_language_versions": { "zh-Hant": "2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html" } }, { "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "date": "2026-06-27", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "胰臟癌", "RAS", "PRMT5", "MAT2A", "臨床數據", "生技投資", "BD" ], "summary": "胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。", "alternate_language_versions": { "en": "2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html" } }, { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "GLP-1", "tirzepatide", "Zepbound", "Taltz", "Omvoh", "immunometabolism", "autoimmune disease", "psoriasis", "IBD", "Eli Lilly" ], "summary": "Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.", "alternate_language_versions": { "zh-Hant": "2026-06-26-tirzepatide-autoimmune-immunometabolism.html" } }, { "title": "神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？", "date": "2026-06-26", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "GLP-1", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。", "alternate_language_versions": { "en": "2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html" } }, { "title": "Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet", "date": "2026-06-25", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Protect Biotech", "Companion Animal Medicine", "Pet Precision Medicine", "Platform Company", "Biotech Investing", "Roche", "Animal Health" ], "summary": "As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is whether a platform company can connect drugs, diagnostics, veterinary clinics, regulation, manufacturing, channels, and data into one defensible system.", "alternate_language_versions": { "zh-Hant": "2026-06-25-protect-pet-medical-roche-platform.html" } }, { "title": "邁向「寵物醫療界羅氏」的寶泰生醫", "date": "2026-06-25", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "寶泰生醫", "寵物醫療", "羅氏", "平台型公司", "生技投資", "製藥巨頭" ], "summary": "當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。", "alternate_language_versions": { "en": "2026-06-25-protect-pet-medical-roche-platform-en.html" } }, { "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "date": "2026-06-24", "language": "en", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "AI drug discovery", "zasocitinib", "Takeda", "Sotyktu", "TYK2", "psoriasis", "PASI 100", "Schrodinger", "biotech investing", "Big Pharma" ], "summary": "Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test.", "alternate_language_versions": { "zh-Hant": "2026-06-24-ai-zasocitinib-sotyktu.html" } }, { "title": "AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu", "date": "2026-06-24", "language": "zh-Hant", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html", "category": "商業分析系列", "access": "免費文章", "tags": [ "AI", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…", "alternate_language_versions": { "en": "2026-06-24-ai-zasocitinib-sotyktu-en.html" } } ], "entities": [ { "name": "Drug development", "type": "topic", "mentions": 36, "latest_date": "2026-06-12", "latest_articles": [ { "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "date": "2026-06-12", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "language": "en" }, { "title": "Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital", "date": "2026-06-11", "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "language": "en" }, { "title": "RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War", "date": "2026-06-10", "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html", "language": "en" }, { "title": "Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories", "date": "2026-06-10", "url": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html", "language": "en" }, { "title": "The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era", "date": "2026-06-09", "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html", "language": "en" } ] }, { "name": "Biotech business analysis", "type": "topic", "mentions": 35, "latest_date": "2026-06-11", "latest_articles": [ { "title": "Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital", "date": "2026-06-11", "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "language": "en" }, { "title": "RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War", "date": "2026-06-10", "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html", "language": "en" }, { "title": "Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories", "date": "2026-06-10", "url": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html", "language": "en" }, { "title": "The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era", "date": "2026-06-09", "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html", "language": "en" }, { "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "language": "en" } ] }, { "name": "生技投資", "type": "market_topic", "mentions": 32, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" }, { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "language": "zh-Hant" }, { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant" } ] }, { "name": "BD", "type": "market_topic", "mentions": 25, "latest_date": "2026-07-07", "latest_articles": [ { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" }, { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant" }, { "title": "拒絕被併購的 RevMed：Biotech 的獨立時代", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html", "language": "zh-Hant" }, { "title": "合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？", "date": "2026-07-02", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html", "language": "zh-Hant" } ] }, { "name": "臨床數據", "type": "market_topic", "mentions": 23, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" }, { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "language": "zh-Hant" }, { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant" } ] }, { "name": "Business Analysis", "type": "topic", "mentions": 19, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet", "date": "2026-06-25", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "language": "en" } ] }, { "name": "GLP-1", "type": "biotech_concept_or_target", "mentions": 16, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" }, { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "language": "en" }, { "title": "神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html", "language": "zh-Hant" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" } ] }, { "name": "FDA", "type": "market_topic", "mentions": 15, "latest_date": "2026-07-04", "latest_articles": [ { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant" }, { "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "language": "en" }, { "title": "CAR-T 迎接新時代：從血癌走向自體免疫", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html", "language": "zh-Hant" }, { "title": "⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣", "date": "2026-05-31", "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html", "language": "zh-Hant" } ] }, { "name": "製藥巨頭", "type": "market_topic", "mentions": 14, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" }, { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "拒絕被併購的 RevMed：Biotech 的獨立時代", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html", "language": "zh-Hant" }, { "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html", "language": "zh-Hant" } ] }, { "name": "Big Pharma", "type": "market_topic", "mentions": 14, "latest_date": "2026-07-07", "latest_articles": [ { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "language": "en" }, { "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "date": "2026-06-12", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "language": "en" } ] }, { "name": "Capital markets", "type": "market_topic", "mentions": 13, "latest_date": "2026-06-29", "latest_articles": [ { "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "date": "2026-06-29", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "language": "en" }, { "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "language": "en" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" }, { "title": "Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy", "date": "2026-06-20", "url": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html", "language": "en" }, { "title": "Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science", "date": "2026-06-14", "url": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html", "language": "en" } ] }, { "name": "Regulatory risk", "type": "topic", "mentions": 13, "latest_date": "2026-06-28", "latest_articles": [ { "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "language": "en" }, { "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "language": "en" }, { "title": "The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal", "date": "2026-05-31", "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html", "language": "en" }, { "title": "Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity", "date": "2026-05-24", "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html", "language": "en" }, { "title": "How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow", "date": "2026-05-22", "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html", "language": "en" } ] }, { "name": "CAR-T", "type": "biotech_concept_or_target", "mentions": 11, "latest_date": "2026-07-06", "latest_articles": [ { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "language": "zh-Hant" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html", "language": "zh-Hant" }, { "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "language": "en" }, { "title": "CAR-T 迎接新時代：從血癌走向自體免疫", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html", "language": "zh-Hant" } ] }, { "name": "Obesity medicine", "type": "topic", "mentions": 11, "latest_date": "2026-06-22", "latest_articles": [ { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" }, { "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "language": "en" }, { "title": "Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?", "date": "2026-06-16", "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html", "language": "en" }, { "title": "Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital", "date": "2026-06-11", "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "language": "en" }, { "title": "Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena", "date": "2026-06-04", "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html", "language": "en" } ] }, { "name": "Business development", "type": "topic", "mentions": 11, "latest_date": "2026-06-12", "latest_articles": [ { "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "date": "2026-06-12", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "language": "en" }, { "title": "Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital", "date": "2026-06-11", "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "language": "en" }, { "title": "The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era", "date": "2026-06-09", "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html", "language": "en" }, { "title": "Old Targets Are Crowded, but They Can Still Make Money", "date": "2026-06-06", "url": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html", "language": "en" }, { "title": "Biotech Investing Needs a Judgment System, Not More News", "date": "2026-05-28", "url": "https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html", "language": "en" } ] }, { "name": "ADC", "type": "biotech_concept_or_target", "mentions": 10, "latest_date": "2026-07-07", "latest_articles": [ { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" }, { "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "language": "en" }, { "title": "2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html", "language": "zh-Hant" }, { "title": "HIV 新藥很好賺呀...吉利德財報披露", "date": "2026-05-19", "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html", "language": "zh-Hant" } ] }, { "name": "Clinical and CMC", "type": "biotech_concept_or_target", "mentions": 10, "latest_date": "2026-06-08", "latest_articles": [ { "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "language": "en" }, { "title": "Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug", "date": "2026-06-05", "url": "https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html", "language": "en" }, { "title": "A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era", "date": "2026-06-03", "url": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html", "language": "en" }, { "title": "Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?", "date": "2026-06-02", "url": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html", "language": "en" }, { "title": "The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal", "date": "2026-05-31", "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html", "language": "en" } ] }, { "name": "AI drug discovery", "type": "topic", "mentions": 9, "latest_date": "2026-06-24", "latest_articles": [ { "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "language": "en" }, { "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "date": "2026-06-12", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "language": "en" }, { "title": "Drugmakers Without AI Capability May No Longer Be Called Drugmakers", "date": "2026-06-07", "url": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html", "language": "en" }, { "title": "Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming", "date": "2026-05-29", "url": "https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html", "language": "en" }, { "title": "The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio", "date": "2026-05-27", "url": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html", "language": "en" } ] }, { "name": "CNS", "type": "topic", "mentions": 9, "latest_date": "2026-06-02", "latest_articles": [ { "title": "Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?", "date": "2026-06-02", "url": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html", "language": "en" }, { "title": "Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity", "date": "2026-05-24", "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html", "language": "en" }, { "title": "OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間", "date": "2026-05-24", "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html", "language": "zh-Hant" }, { "title": "How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow", "date": "2026-05-22", "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html", "language": "en" }, { "title": "這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流", "date": "2026-05-22", "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html", "language": "zh-Hant" } ] }, { "name": "Taiwan biotech", "type": "topic", "mentions": 8, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" } ] }, { "name": "clinical data", "type": "market_topic", "mentions": 7, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" } ] }, { "name": "drug development", "type": "topic", "mentions": 7, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" } ] }, { "name": "RAS", "type": "biotech_concept_or_target", "mentions": 7, "latest_date": "2026-07-02", "latest_articles": [ { "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "date": "2026-07-02", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "language": "en" }, { "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "language": "en" }, { "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "language": "zh-Hant" }, { "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "language": "en" }, { "title": "2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html", "language": "zh-Hant" } ] }, { "name": "biotech business analysis", "type": "topic", "mentions": 6, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" } ] }, { "name": "biotech valuation", "type": "market_topic", "mentions": 6, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" } ] }, { "name": "Targeted therapy", "type": "topic", "mentions": 6, "latest_date": "2026-05-19", "latest_articles": [ { "title": "HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal", "date": "2026-05-19", "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html", "language": "en" }, { "title": "Where Pfizer Misjudged the Vepdegestrant Strategy", "date": "2026-05-18", "url": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html", "language": "en" }, { "title": "Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs", "date": "2026-05-17", "url": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html", "language": "en" }, { "title": "Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster", "date": "2026-05-17", "url": "https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html", "language": "en" }, { "title": "How PharmaEssentia's Besremi Opens a Larger Valuation Imagination", "date": "2026-05-14", "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html", "language": "en" } ] }, { "name": "BD licensing", "type": "market_topic", "mentions": 5, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" }, { "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "language": "en" } ] }, { "name": "AI", "type": "topic", "mentions": 5, "latest_date": "2026-06-24", "latest_articles": [ { "title": "AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html", "language": "zh-Hant" }, { "title": "【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】", "date": "2026-06-20", "url": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html", "language": "zh-Hant" }, { "title": "GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法", "date": "2026-06-19", "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html", "language": "zh-Hant" }, { "title": "AI製藥下半場：讓藥活下來", "date": "2026-06-13", "url": "https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html", "language": "zh-Hant" }, { "title": "沒有 AI 能力的藥廠，將不再被稱作藥廠", "date": "2026-06-07", "url": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html", "language": "zh-Hant" } ] }, { "name": "Pfizer", "type": "company", "mentions": 5, "latest_date": "2026-06-22", "latest_articles": [ { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" }, { "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "language": "en" }, { "title": "HIV 新藥很好賺呀...吉利德財報披露", "date": "2026-05-19", "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html", "language": "zh-Hant" }, { "title": "大藥廠 輝瑞在兩個判斷上栽跟頭？", "date": "2026-05-18", "url": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html", "language": "zh-Hant" }, { "title": "中樞神經新藥要靠「神經發炎」？", "date": "2026-05-13", "url": "https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html", "language": "zh-Hant" } ] }, { "name": "Company Research", "type": "topic", "mentions": 5, "latest_date": "2026-06-10", "latest_articles": [ { "title": "RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War", "date": "2026-06-10", "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html", "language": "en" }, { "title": "Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena", "date": "2026-06-04", "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html", "language": "en" }, { "title": "Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means", "date": "2026-06-01", "url": "https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html", "language": "en" }, { "title": "Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers", "date": "2026-05-27", "url": "https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html", "language": "en" }, { "title": "A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion", "date": "2026-05-20", "url": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html", "language": "en" } ] }, { "name": "Immunology", "type": "topic", "mentions": 5, "latest_date": "2026-06-08", "latest_articles": [ { "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "language": "en" }, { "title": "A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era", "date": "2026-06-03", "url": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html", "language": "en" }, { "title": "The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal", "date": "2026-05-31", "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html", "language": "en" }, { "title": "Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets", "date": "2026-05-25", "url": "https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html", "language": "en" }, { "title": "The Autoimmune Twins That Could Save Johnson & Johnson", "date": "2026-05-12", "url": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html", "language": "en" } ] }, { "name": "capital markets", "type": "market_topic", "mentions": 4, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" }, { "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "language": "en" } ] }, { "name": "Free Article", "type": "topic", "mentions": 4, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en" } ] }, { "name": "Biotech investing", "type": "topic", "mentions": 4, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "date": "2026-06-29", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "language": "en" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" }, { "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "date": "2026-06-12", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "language": "en" } ] }, { "name": "Eli Lilly", "type": "company", "mentions": 4, "latest_date": "2026-06-26", "latest_articles": [ { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "language": "en" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" }, { "title": "Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?", "date": "2026-06-16", "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html", "language": "en" }, { "title": "Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場", "date": "2026-06-04", "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html", "language": "zh-Hant" } ] }, { "name": "藥華藥", "type": "topic", "mentions": 4, "latest_date": "2026-05-23", "latest_articles": [ { "title": "全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價", "date": "2026-05-23", "url": "https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html", "language": "zh-Hant" }, { "title": "這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流", "date": "2026-05-22", "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html", "language": "zh-Hant" }, { "title": "AI半導體掩蓋生技光芒", "date": "2026-05-21", "url": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html", "language": "zh-Hant" }, { "title": "藥華藥 打開估值想像空間", "date": "2026-05-14", "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html", "language": "zh-Hant" } ] }, { "name": "台灣生技", "type": "topic", "mentions": 3, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" }, { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "language": "zh-Hant" } ] }, { "name": "PRMT5", "type": "biotech_concept_or_target", "mentions": 3, "latest_date": "2026-07-02", "latest_articles": [ { "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "date": "2026-07-02", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "language": "en" }, { "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "language": "en" }, { "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "language": "zh-Hant" } ] }, { "name": "疫苗", "type": "topic", "mentions": 3, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html", "language": "zh-Hant" }, { "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html", "language": "zh-Hant" }, { "title": "禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？", "date": "2026-06-16", "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html", "language": "zh-Hant" } ] }, { "name": "M&A", "type": "topic", "mentions": 3, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "language": "en" }, { "title": "Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?", "date": "2026-06-16", "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html", "language": "en" } ] }, { "name": "Oncology", "type": "topic", "mentions": 3, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer", "date": "2026-06-21", "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html", "language": "en" }, { "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "language": "en" } ] }, { "name": "BESREMi", "type": "topic", "mentions": 3, "latest_date": "2026-05-22", "latest_articles": [ { "title": "這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流", "date": "2026-05-22", "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html", "language": "zh-Hant" }, { "title": "AI半導體掩蓋生技光芒", "date": "2026-05-21", "url": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html", "language": "zh-Hant" }, { "title": "藥華藥 打開估值想像空間", "date": "2026-05-14", "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html", "language": "zh-Hant" } ] }, { "name": "J&J", "type": "topic", "mentions": 3, "latest_date": "2026-05-19", "latest_articles": [ { "title": "HIV 新藥很好賺呀...吉利德財報披露", "date": "2026-05-19", "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html", "language": "zh-Hant" }, { "title": "Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T", "date": "2026-05-17", "url": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html", "language": "zh-Hant" }, { "title": "自體免疫 雙子星 拯救 嬌生", "date": "2026-05-12", "url": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html", "language": "zh-Hant" } ] }, { "name": "代謝疾病", "type": "topic", "mentions": 2, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" }, { "title": "減肥成王：GLP-1 正在把全球生技資本重新洗牌", "date": "2026-06-11", "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html", "language": "zh-Hant" } ] }, { "name": "API / CDMO", "type": "topic", "mentions": 2, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" } ] }, { "name": "dorzagliatin", "type": "topic", "mentions": 2, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" } ] }, { "name": "GKA", "type": "topic", "mentions": 2, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" } ] }, { "name": "glucokinase activator", "type": "topic", "mentions": 2, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" } ] }, { "name": "MASH", "type": "topic", "mentions": 2, "latest_date": "2026-07-08", "latest_articles": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en" }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant" } ] }, { "name": "oncology", "type": "topic", "mentions": 2, "latest_date": "2026-07-07", "latest_articles": [ { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "date": "2026-07-02", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "language": "en" } ] }, { "name": "PD-1/VEGF", "type": "biotech_concept_or_target", "mentions": 2, "latest_date": "2026-07-07", "latest_articles": [ { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en" }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant" } ] }, { "name": "細胞治療", "type": "topic", "mentions": 2, "latest_date": "2026-07-06", "latest_articles": [ { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "language": "zh-Hant" }, { "title": "CAR-T 迎接新時代：從血癌走向自體免疫", "date": "2026-06-08", "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html", "language": "zh-Hant" } ] }, { "name": "autoimmune disease", "type": "topic", "mentions": 2, "latest_date": "2026-07-06", "latest_articles": [ { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en" }, { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "language": "en" } ] }, { "name": "生技估值", "type": "market_topic", "mentions": 2, "latest_date": "2026-07-05", "latest_articles": [ { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "台灣生技估值第一步：不要把所有公司都塞進同一個本益比", "date": "2026-05-27", "url": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html", "language": "zh-Hant" } ] }, { "name": "併購", "type": "topic", "mentions": 2, "latest_date": "2026-07-05", "latest_articles": [ { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "70億美元核藥併購傳聞：Curium想買Lantheus，真正買的是一張核藥時代的入場券", "date": "2026-06-09", "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html", "language": "zh-Hant" } ] }, { "name": "新藥開發", "type": "topic", "mentions": 2, "latest_date": "2026-07-05", "latest_articles": [ { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant" }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant" } ] }, { "name": "HHS", "type": "topic", "mentions": 2, "latest_date": "2026-07-04", "latest_articles": [ { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en" }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant" } ] }, { "name": "Revolution Medicines", "type": "company", "mentions": 2, "latest_date": "2026-07-03", "latest_articles": [ { "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "language": "en" }, { "title": "Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science", "date": "2026-06-14", "url": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html", "language": "en" } ] }, { "name": "ADHD", "type": "topic", "mentions": 2, "latest_date": "2026-07-01", "latest_articles": [ { "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "language": "en" }, { "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "language": "zh-Hant" } ] }, { "name": "centanafadine", "type": "topic", "mentions": 2, "latest_date": "2026-07-01", "latest_articles": [ { "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "language": "en" }, { "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "language": "zh-Hant" } ] }, { "name": "Otsuka", "type": "topic", "mentions": 2, "latest_date": "2026-07-01", "latest_articles": [ { "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "language": "en" }, { "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "language": "zh-Hant" } ] }, { "name": "GSK", "type": "company", "mentions": 2, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases", "date": "2026-06-19", "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html", "language": "en" } ] }, { "name": "Lung cancer", "type": "topic", "mentions": 2, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases", "date": "2026-06-19", "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html", "language": "en" } ] }, { "name": "Nuvalent", "type": "topic", "mentions": 2, "latest_date": "2026-06-30", "latest_articles": [ { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en" }, { "title": "GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases", "date": "2026-06-19", "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html", "language": "en" } ] }, { "name": "Regeneron", "type": "topic", "mentions": 2, "latest_date": "2026-06-29", "latest_articles": [ { "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "date": "2026-06-29", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "language": "en" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" } ] }, { "name": "感染症", "type": "topic", "mentions": 2, "latest_date": "2026-06-28", "latest_articles": [ { "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html", "language": "zh-Hant" }, { "title": "禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？", "date": "2026-06-16", "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html", "language": "zh-Hant" } ] }, { "name": "胰臟癌", "type": "topic", "mentions": 2, "latest_date": "2026-06-27", "latest_articles": [ { "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "language": "zh-Hant" }, { "title": "RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰", "date": "2026-06-10", "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html", "language": "zh-Hant" } ] }, { "name": "Biotech Investing", "type": "topic", "mentions": 2, "latest_date": "2026-06-27", "latest_articles": [ { "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "language": "en" }, { "title": "Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet", "date": "2026-06-25", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "language": "en" } ] }, { "name": "MAT2A", "type": "biotech_concept_or_target", "mentions": 2, "latest_date": "2026-06-27", "latest_articles": [ { "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "language": "en" }, { "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "language": "zh-Hant" } ] }, { "name": "biotech investing", "type": "topic", "mentions": 2, "latest_date": "2026-06-26", "latest_articles": [ { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "language": "en" }, { "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "language": "en" } ] }, { "name": "psoriasis", "type": "topic", "mentions": 2, "latest_date": "2026-06-26", "latest_articles": [ { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "language": "en" }, { "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "language": "en" } ] }, { "name": "Roche", "type": "company", "mentions": 2, "latest_date": "2026-06-25", "latest_articles": [ { "title": "Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet", "date": "2026-06-25", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "language": "en" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" } ] }, { "name": "Novo Nordisk", "type": "company", "mentions": 2, "latest_date": "2026-06-22", "latest_articles": [ { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en" }, { "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "language": "en" } ] }, { "name": "Keytruda", "type": "topic", "mentions": 2, "latest_date": "2026-06-21", "latest_articles": [ { "title": "Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer", "date": "2026-06-21", "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html", "language": "en" }, { "title": "藥王的最佳搭檔？療效翻倍！", "date": "2026-05-30", "url": "https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html", "language": "zh-Hant" } ] }, { "name": "PD-1 VEGF", "type": "biotech_concept_or_target", "mentions": 2, "latest_date": "2026-06-21", "latest_articles": [ { "title": "Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer", "date": "2026-06-21", "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html", "language": "en" }, { "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "language": "en" } ] }, { "name": "Ecnoglutide", "type": "topic", "mentions": 2, "latest_date": "2026-06-17", "latest_articles": [ { "title": "GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html", "language": "zh-Hant" }, { "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "language": "en" } ] }, { "name": "Wegovy", "type": "topic", "mentions": 2, "latest_date": "2026-06-17", "latest_articles": [ { "title": "GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html", "language": "zh-Hant" }, { "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "date": "2026-06-17", "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "language": "en" } ] }, { "name": "ASCO", "type": "topic", "mentions": 2, "latest_date": "2026-06-15", "latest_articles": [ { "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "language": "en" }, { "title": "2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代", "date": "2026-06-15", "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html", "language": "zh-Hant" } ] }, { "name": "Biotech", "type": "topic", "mentions": 2, "latest_date": "2026-06-13", "latest_articles": [ { "title": "The Next Phase of AI Drug Development: Making Molecules Survive as Drugs", "date": "2026-06-13", "url": "https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html", "language": "en" }, { "title": "老靶點都很捲，但不是不能賺錢", "date": "2026-06-06", "url": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html", "language": "zh-Hant" } ] }, { "name": "AI 製藥", "type": "topic", "mentions": 2, "latest_date": "2026-06-12", "latest_articles": [ { "title": "盤點整理，AI藥物開發走得如何了？", "date": "2026-06-12", "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html", "language": "zh-Hant" }, { "title": "破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元", "date": "2026-05-20", "url": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html", "language": "zh-Hant" } ] } ], "market_attention_signals": [ { "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "GLP-1", "dorzagliatin", "glucokinase activator", "GKA" ], "summary": "GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy." }, { "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "date": "2026-07-08", "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "GLP-1", "dorzagliatin", "多格列艾汀", "glucokinase activator", "GKA", "代謝疾病", "糖尿病", "MASH" ], "summary": "GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。" }, { "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "ADC", "PD-1/VEGF", "bispecific antibody", "oncology" ], "summary": "After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone." }, { "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "date": "2026-07-07", "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "ADC", "PD-1/VEGF", "雙特異性抗體", "BD", "臨床數據", "生技投資", "腫瘤藥物", "製藥巨頭" ], "summary": "sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。" }, { "title": "通用型 CAR-T 的 2026 從低谷回暖", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "臨床數據", "生技投資", "細胞治療", "CAR-T", "異體細胞治療", "自體免疫疾病", "台灣生技" ], "summary": "邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。" }, { "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "date": "2026-07-06", "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "cell therapy", "CAR-T", "allogeneic cell therapy", "clinical data" ], "summary": "Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table." }, { "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "併購", "臨床數據", "生技投資", "製藥巨頭", "新藥開發", "生技估值" ], "summary": "2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。" }, { "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "date": "2026-07-05", "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Business Analysis", "Free Article", "biotech business analysis", "Taiwan biotech", "BD licensing", "biotech M&A", "biotech valuation", "clinical data" ], "summary": "In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait." }, { "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "HHS", "FDA", "Operation TrialBlazer", "clinical trial reform", "biotech business analysis", "Taiwan biotech", "drug development", "clinical data" ], "summary": "Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy." }, { "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "date": "2026-07-04", "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "臨床數據", "生技投資", "FDA", "HHS", "臨床試驗", "新藥開發" ], "summary": "2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。" }, { "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Revolution Medicines", "RevMed", "daraxonrasib", "RAS oncology", "biotech business analysis", "Taiwan biotech", "BD licensing", "biotech valuation" ], "summary": "Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies." }, { "title": "拒絕被併購的 RevMed：Biotech 的獨立時代", "date": "2026-07-03", "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。" }, { "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "date": "2026-07-02", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "synthetic lethality", "PARP", "PRMT5", "MTAP", "RAS", "oncology", "biomarkers", "Taiwan biotech" ], "summary": "PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce." }, { "title": "合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？", "date": "2026-07-02", "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "BD", "臨床數據", "生技投資" ], "summary": "2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。" }, { "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "ADHD", "centanafadine", "Otsuka", "clinical data", "neuroscience", "non-stimulant ADHD therapy", "Taiwan biotech", "drug development" ], "summary": "Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention." }, { "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "date": "2026-07-01", "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "ADHD", "centanafadine", "Otsuka", "臨床數據", "神經科學", "美時", "瑩碩生技" ], "summary": "Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。" }, { "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "GSK", "Nuvalent", "Oncology", "Lung cancer", "ROS1", "ALK", "BD", "M&A" ], "summary": "GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table." }, { "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌", "date": "2026-06-30", "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "疫苗", "BD", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。" }, { "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "date": "2026-06-29", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Biotech IPO", "Parabilis Medicines", "Helicons", "Zolucatetide", "Wnt beta-catenin", "Regeneron", "Biotech investing", "Capital markets" ], "summary": "Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up." }, { "title": "美股迎來史上最大 Biotech IPO", "date": "2026-06-29", "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "臨床數據", "生技投資" ], "summary": "台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。" }, { "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "FDA", "Biotech rebound", "Regulatory risk", "Rare disease", "Gene therapy", "mRNA vaccines", "M&A", "Capital markets" ], "summary": "Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets." }, { "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起", "date": "2026-06-28", "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "疫苗", "感染症", "BD", "臨床數據", "生技投資" ], "summary": "代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。" }, { "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Pancreatic Cancer", "RAS", "PRMT5", "MAT2A", "Synthetic Lethality", "Clinical Data", "Biotech Investing", "BD" ], "summary": "Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies." }, { "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "date": "2026-06-27", "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "胰臟癌", "RAS", "PRMT5", "MAT2A", "臨床數據", "生技投資", "BD" ], "summary": "胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。" }, { "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "GLP-1", "tirzepatide", "Zepbound", "Taltz", "Omvoh", "immunometabolism", "autoimmune disease", "psoriasis" ], "summary": "Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases." }, { "title": "神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？", "date": "2026-06-26", "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "GLP-1", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。" }, { "title": "邁向「寵物醫療界羅氏」的寶泰生醫", "date": "2026-06-25", "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "寶泰生醫", "寵物醫療", "羅氏", "平台型公司", "生技投資", "製藥巨頭" ], "summary": "當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。" }, { "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "AI drug discovery", "zasocitinib", "Takeda", "Sotyktu", "TYK2", "psoriasis", "PASI 100", "Schrodinger" ], "summary": "Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test." }, { "title": "AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu", "date": "2026-06-24", "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html", "language": "zh-Hant", "category": "商業分析系列", "access": "免費文章", "tags": [ "AI", "臨床數據", "生技投資", "製藥巨頭" ], "summary": "過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…" }, { "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "date": "2026-06-22", "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "language": "en", "category": "商業分析系列", "access": "免費文章", "tags": [ "Obesity medicine", "GLP-1", "Eli Lilly", "Novo Nordisk", "Pfizer", "Roche", "AstraZeneca", "Regeneron" ], "summary": "Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved." } ] }